Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Global assessment of partial artemisinin resistance: multicenter trial across Kenya, Peru, and Thailand in patients with uncomplicated Plasmodium falciparum malaria.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2025

Same author

Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2025

Same author

Donanemab: Appropriate use recommendations.

The journal of prevention of Alzheimer's disease·2025

Same author

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024

Same author

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.

The journal of prevention of Alzheimer's disease·2024

Same author

Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality.

The journal of prevention of Alzheimer's disease·2024

Search research articles

Related Experiment Video

Updated: Jul 12, 2025

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

Geroscience and Alzheimer's Disease Drug Development.

J Cummings¹, A M Leisgang Osse, J Kinney

¹Jeffrey Cummings, 1380 Opal valley street, Henderson, Nevada 89052, USA, jcummings@cnsinnovations.com.

The Journal of Prevention of Alzheimer'S Disease

|October 24, 2023

Summary

Aging significantly impacts Alzheimer's disease (AD) clinical trials. Incorporating older adults and age-relevant assessments can improve trial generalizability and therapeutic understanding for aging populations.

Keywords:

Geroscience, Alzheimer’s disease aging drug development pipeline senolytics

More Related Videos

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Related Experiment Videos

Last Updated: Jul 12, 2025

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Area of Science:

Gerontology
Neuroscience
Clinical Pharmacology

Background:

Age is the primary risk factor for Alzheimer's disease (AD), yet clinical trials often enroll younger, healthier participants.
The broad age range (50-90 years) in AD trials encompasses substantial age-related physiological changes.
Current drug development may not fully account for aging's influence on clinical trial outcomes.

Purpose of the Study:

To advocate for a geroscience perspective in Alzheimer's disease drug development.
To propose adjustments in clinical trial methodologies to better reflect the aging process.
To enhance the understanding of AD therapies' efficacy and applicability in older populations.

Main Methods:

Inclusion of older adults in early-phase (Phase 1) multiple ascending dose studies.
Utilization of geriatric-specific clinical outcomes and biomarkers in Phase 2 trials.
Application of Phase 2 learnings to Phase 3 studies for comprehensive aging insights.

Main Results:

The AD trial pipeline now includes diverse targets beyond amyloid beta and tau, with many interventions addressing age-related conditions.
Anti-inflammatory, bioenergetic, and metabolic therapies are prominent classes applicable to both AD and other aging disorders.
Adjusted drug development strategies can yield better trial outcomes for aged individuals.

Conclusions:

Integrating comprehensive geriatric assessments and aging-relevant biomarkers is crucial for AD clinical trials.
Focusing on aging's role improves the understanding of AD therapies and their generalizability to the broader AD patient population.
A geroscience-informed approach ensures trial findings are more representative of and applicable to aging individuals with Alzheimer's disease.